HK Stock Market Move | HANSOH PHARMA (03692) rises over 7% on entering into strategic collaboration and license agreement with Roche, with potential milestone payments exceeding US$15 billion.

HANSOH PHARMA (03692) rose over 7% in morning trading, up 7.06% as of press time to HK$34, with turnover of HK$200 million. On the news front, HANSOH PHARMA announced that on October 17, 2026, its wholly-owned subsidiaries Shanghai Hansoh Biomedical Co., Ltd., Changzhou Hengbang Pharmaceutical Co., Ltd., and Hansoh Bio, LLC (collectively "Hansoh") entered into a strategic collaboration and license agreement with F. Hoffmann-La Roche Ltd (Roche). The strategic collaboration covers a portfolio comprising a series of antibody-drug conjugate (ADC) programs, including two Hansoh preclinical ADC programs and multiple ADC programs directed at targets proposed by Roche and developed leveraging Hansoh's proprietary ADC technology platform. Under the collaboration agreement, Hansoh will lead early development of these programs, up to completion of global Phase Ia clinical trials. Roche will be responsible for further development of these programs globally (excluding Mainland China, Hong Kong, Macau, and Taiwan). Hansoh retains all rights to develop, register, and commercialize these programs in Mainland China, Hong Kong, Macau, and Taiwan. Hansoh will receive a US$400 million upfront payment and a US$110 million one-year anniversary payment, and is eligible to receive potential milestone payments exceeding US$15 billion based on the development, registration, and commercialization progress of these programs, as well as tiered royalties based on potential future product sales.